A multicenter, randomized, double-blinded, parallel-design study to evaluate the lipid-altering efficacy of 2 formulations of MK0524A [niacin/laropiprant] compared to Niaspan (TM) [niacin]
Latest Information Update: 09 May 2022
Price :
$35 *
At a glance
- Drugs Niacin/laropiprant (Primary) ; Niacin
- Indications Hypercholesterolaemia
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 06 Oct 2007 New trial record.